Freakonomics Radio
Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
- SOURCES:
- Chris Snyder, professor of economics at Dartmouth College.
- David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
- Heather Stone, health science policy analyst at the Food & Drug Administration.
- Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.
- RESOURCES:
- Chasing My Cure: A Doctor’s Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
- Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
- Market Shaping Accelerator.
- CURE ID Registry.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
596. Farewell to a Generational Talent
Daniel Kahneman left his mark on academia (and the real world) in countless ways. A group of his friends and colleagues recently gathered in Chicago to reflect on this legacy — and we were there,…
595. Why Don’t We Have Better Candidates for President?
American politics is trapped in a duopoly, with two all-powerful parties colluding to stifle competition. We revisit a 2018 episode to explain how the political industry works, and talk to a reformer (and former presidential…
594. Your Brand’s Spokesperson Just Got Arrested — Now What?
It’s hard to know whether the benefits of hiring a celebrity are worth the risk. We dig into one gruesome story of an endorsement gone wrong, and find a surprising result. SOURCES: John Cawley,…
593. You Can Make a Killing, but Not a Living
Broadway operates on a winner-take-most business model. A runaway hit like Stereophonic — which just won five Tony Awards — will create a few big winners. But even the stars of the show will have…
EXTRA: The Fascinatingly Mundane Secrets of the World’s Most Exclusive Nightclub
The Berlin dance mecca Berghain is known for its eight-hour line and inscrutable door policy. PJ Vogt, host of the podcast Search Engine, joins us to crack the code. It has to do with Cold…
592. How to Make the Coolest Show on Broadway
Hit by Covid, runaway costs, and a zillion streams of competition, serious theater is in serious trouble. A new hit play called Stereophonic — the most Tony-nominated play in history — has something to say…
591. Signs of Progress, One Year at a Time
Every December, a British man named Tom Whitwell publishes a list of 52 things he’s learned that year. These fascinating facts reveal the spectrum of human behavior, from fraud and hypocrisy to Whitwell’s steadfast belief…
EXTRA: The Opioid Tragedy — How We Got Here
An update of our 2020 series, in which we spoke with physicians, researchers, and addicts about the root causes of the crisis — and the tension between abstinence and harm reduction. SOURCES: Gail D’Onofrio, professor…
590. Can $55 Billion End the Opioid Epidemic?
Thanks to legal settlements with drug makers and distributors, states have plenty of money to boost prevention and treatment. Will it work? (Part two of a two-part series.) SOURCES: Keith Humphreys, professor of psychiatry…
589. Why Has the Opioid Crisis Lasted So Long?
Most epidemics flare up, do their damage, and fade away. This one has been raging for almost 30 years. To find out why, it’s time to ask some uncomfortable questions. (Part one of a two-part…